Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea

Transplantation

Volumn 87, Issue 8, 2009, Pages 1225-1231

  Jun, Kyung Ran ^a   Lee, Woochang ^a   Jang, Mi Sook ^a   Chun, Sail ^a   Song, Gi Won ^a   Park, Kwan Tae ^a   Lee, Sung Gyu ^a   Han, Duck Jong ^a   Kang, Changwon ^b   Cho, Dae Yeon ^c   Kim, Jin Q ^d   Min, Won Ki ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

^c Doo San Engineering Center   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

ABCB1; CYP3A; Polymorphism; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; TACROLIMUS; ABCB1 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; PRIMER DNA;

ACUTE GRAFT REJECTION; ADULT; AGED; ALLELE; ARTICLE; CHRONIC GRAFT REJECTION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENOTYPE; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; KOREA; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; ORGAN DONOR; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; BLOOD; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENETICS; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

CYTOCHROME P-450 CYP3A; DNA PRIMERS; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; ORGAN TRANSPLANTATION; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; TACROLIMUS;

EID: 65549149071     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31819f117e     Document Type: Article

References (24)

1. First MR. Tacrolimus based immunosuppression. J Nephrol 2004; 17 (suppl 8): S25.
2. Masuda S, Inui K. An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients. Pharmacol Ther 2006; 112: 184.
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623.
4. Zhang X, Liu ZH, Zheng JM, et al. Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation. Clin Transplant 2005; 19: 638.
5. Mourad M, Mourad G, Wallemacq P, et al. Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation 2005; 80: 977.
6. Yu SF,WuLH, Zheng SS. Genetic factors for individual administration of immunosuppressants in organ transplantation. Hepatobiliary Pancreat Dis Int 2006; 5: 337.
7. Zhao Y, Song M, Guan D, et al. Genetic polymorphisms of CYP3A5 genes and concentration of the cyclosporine and tacrolimus. Transplant Proc 2005; 37: 178.
8. Saeki M, Saito Y, Nakamura T, et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat 2003; 21: 653.
9. Zhu B, Chen GL, Chen XP, et al. Genotype of CYP3AP1 associated with CYP3A activity in Chinese Han population. Acta Pharmacol Sin 2002; 23: 567.
10. Xin X, Luan X, Xiao J, et al. Association study of four activity SNPs of CYP3A4 with the precocious puberty in Chinese girls. Neurosci Lett 2005; 381: 284.
11. Dai D, Tang J, Rose R, et al. Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. J Pharmacol Exp Ther 2001; 299: 825.
12. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383.
13. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11: 773.
14. Goh BC, Lee SC, Wang LZ, et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002; 20: 3683.
15. Yu S, Wu L, Jin J, et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 2006; 81: 46.
16. Fukudo M, Yano I, Masuda S, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 2006; 80: 331.
17. Tada H, Tsuchiya N, Satoh S, et al. Impact ofCYP3A5andMDR1(ABCB1) C3435T polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients. Transplant Proc 2005; 37: 1730.
18. Macphee IA, Fredericks S, Tai T, et al. Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 2002; 74: 1486.
19. Rodriguez-Antona C, Axelson M, Otter C, et al. A novel polymorphic cytochrome P450 formed by splicing of CYP3A7 and the pseudogene CYP3AP1. J Biol Chem 2005; 280: 28324.
20. Hsieh KP, Lin YY, Cheng CL, et al. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001; 29: 268.
21. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473.
22. Kim RB. MDR1 single nucleotide polymorphisms: Multiplicity of haplotypes and functional consequences. Pharmacogenetics 2002; 12: 425.
23. Goto M, Masuda S, Saito H, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12: 451.
24. Choi JH, Lee YJ, Jang SB, et al. Influence of the CYP3A5 and MDR1 genetic polymorphisms on the pharmacokinetics of tacrolimus in healthy Korean subjects. Br J Clin Pharmacol 2007; 64: 185.